Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Federica Agnello, Salvatore Ingala, Giulia Laterra, Lorenzo Scalia, Marco Barbanti
Atherosclerotic cardiovascular disease (ASCVD) represents a major global health challenge, significantly contributing to mortality rates. This chronic inflammatory condition affecting blood vessels is intricately linked to hypercholesterolemia, with elevated levels of low-density lipoprotein cholesterol (LDL-C) recognized as a central and modifiable risk factor. The effectiveness of lipid-lowering therapy (LLT) in mitigating ASCVD risk is well established, with studies revealing a substantial reduction in major ischemic events correlating with LDL-C reduction...
February 22, 2024: Journal of Clinical Medicine
#2
JOURNAL ARTICLE
Shadi Azam, Rulla M Tamimi, Michele B Drotman, Kemi Babagbemi, Allison D Levy, Jessica M Peña
PURPOSE: Breast arterial calcifications (BAC) are incidentally observed on mammograms, yet their implications remain unclear. We investigated lifestyle, reproductive, and cardiovascular determinants of BAC in women undergoing mammography screening. Further, we investigated the relationship between BAC, coronary arterial calcifications (CAC) and estimated 10-year atherosclerotic cardiovascular (ASCVD) risk. METHODS: In this cross-sectional study, we obtained reproductive history and CVD risk factors from 215 women aged 18 or older who underwent mammography and cardiac computed tomographic angiography (CCTA) within a 2-year period between 2007 and 2017 at hospital...
March 13, 2024: Clinical Imaging
#3
JOURNAL ARTICLE
Dingwei Dai, Joaquim Fernandes, Xiaowu Sun, Laura Lupton, Vaughn W Payne, Alexandra Berk
Background: Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of mortality and disability in the United States and worldwide. Objective: To assess the multimorbidity burden and its associations with adverse cardiovascular events (ACE) and healthcare costs among patients with ASCVD. Methods: This is a retrospective observational cohort study using Aetna claims database. Patients with ASCVD were identified during the study period (1/1/2018-10/31/2021). The earliest ASCVD diagnosis date was identified as the index date...
2024: Journal of health economics and outcomes research
#4
JOURNAL ARTICLE
Kristen Thompson, Brandi L Bowers, Ashley M Evans
BACKGROUND: Despite expanded indications and demonstrated cardiovascular and renal benefits, prescribing rates of SGLT-2 inhibitors are low. OBJECTIVES: The study aimed to identify factors impacting prescriber decision-making when prescribing SGLT-2 inhibitors in the outpatient setting and identify differences across specialties in self-identified prescribing patterns. METHODS: An anonymous survey was administered electronically to prescribers in relevant specialties at a large community health system...
March 14, 2024: Journal of the American Pharmacists Association: JAPhA
#5
JOURNAL ARTICLE
Raman Puri, Manish Bansal, Vimal Mehta, P Barton Duell, Nathan D Wong, S S Iyengar, Dinesh Kalra, Devaki R Nair, Navin C Nanda, Jagat Narula, P Deedwania, Jamal Yusuf, Jamshed J Dalal, Sadanand Shetty, Vinod M Vijan, Rajeev Agarwala, Soumitra Kumar, Kris Vijay, Aziz Khan, Gurpreet Singh Wander, P C Manoria, S K Wangnoo, Viswanathan Mohan, Shashank R Joshi, Balbir Singh, Prafulla Kerkar, Rajesh Rajput, D Prabhakar, Abdul Hamid Zargar, Banshi Saboo, Ravi R Kasliwal, Saumitra Ray, Sandeep Bansal, M U Rabbani, Shibba Takkar Chhabra, Sarat Chandra, Neil Bardoloi, Narasaraju Kavalipati, Immaneni Sathyamurthy, Kunal Mahajan, Akshya Pradhan, N N Khanna, Rajesh Khadgawat, Preeti Gupta, Milan C Chag, Ashu Gupta, A Murugnathan, S N Narasingan, Sundeep Upadhyaya, Vinod Mittal, Rashida Patanwala Melinkeri, Madhur Yadav, M Raseed Mubarak, K K Pareek, Pradeep Kumar Dabla, Rashmi Nanda, J C Mohan
OBJECTIVE: In 2016, the Lipid Association of India (LAI) developed a cardiovascular risk assessment algorithm and defined low-density lipoprotein cholesterol (LDL-C) goals for prevention of atherosclerotic cardiovascular disease (ASCVD) in Indians. The recent refinements in the role of various risk factors and subclinical atherosclerosis in prediction of ASCVD risk necessitated updating the risk algorithm and treatment goals. METHODS: The LAI core committee held twenty-one meetings and webinars from June 2022 to July 2023 with experts across India and critically reviewed the latest evidence regarding the strategies for ASCVD risk prediction and the benefits and modalities for intensive lipid lowering...
February 8, 2024: Journal of Clinical Lipidology
#6
JOURNAL ARTICLE
Icíar Martínez López, Jorge Francisco Gómez Cerezo, José M Gámez, Isabel Egocheaga Cabello, Mar Castellanos, Raquel Campuzano Ruiz, Vivencio Barrios, Vicente Pallarés-Carratalá, José Manuel Rodríguez, Nuria Morant Talamante, Javier Parrondo, José María Mostaza
INTRODUCTION: Atherosclerotic cardiovascular disease (ASCVD) is one of the main causes of morbidity and mortality in developed countries and entails high resources use and costs for health systems. The risk of suffering future cardiovascular (CV) events and the consequent resources use is higher in those patients who have already had a previous cardiovascular event. The objective of the study was to determine the average annual cost of patients with a new or recurrent atherosclerotic CV event during the 2 years after the event...
2024: Frontiers in Cardiovascular Medicine
#7
JOURNAL ARTICLE
Dick C Chan, Gerald F Watts
PURPOSE OF REVIEW: Hypertriglyceridemia (HTG) is an independent and casual risk factor for atherosclerotic cardiovascular disease (ASCVD). There is an unmet need for more effective treatments for patients with HTG. Angiopoietin-like protein 3 (ANGPTL3) and apolipoprotein C-III (apoC-III) are key regulators of triglyceride-rich lipoprotein (TRL) metabolism. We review recent clinical trials targeting ANGPTL3 and apoC-III with monoclonal antibody and nucleic acid therapies, including antisense oligonucleotides and small interfering RNA...
February 20, 2024: Current Opinion in Lipidology
#8
JOURNAL ARTICLE
Sibbeliene E van den Bosch, Barbara A Hutten, Willemijn E Corpeleijn, D Meeike Kusters
PURPOSE OF REVIEW: Familial hypercholesterolemia leads to elevated levels of low-density lipoprotein cholesterol (LDL-C) from birth onwards due to a pathogenetic variation in genes in cholesterol metabolism. Early screening to identify and subsequently treat children with familial hypercholesterolemia is crucial to reduce the risk of premature atherosclerotic cardiovascular disease (ASCVD). This review focuses on recent insights in the field of pediatric familial hypercholesterolemia...
February 15, 2024: Current Opinion in Lipidology
#9
JOURNAL ARTICLE
Navdeep Tangri, Maria K Svensson, Johan Bodegård, Samuel Adamsson Eryd, Marcus Thuresson, Stefan Gustafsson, Tadashi Sofue
BACKGROUND: Kidney-protective treatments (renin-angiotensin system inhibitors [RASis] and sodium-glucose co-transporter-2 inhibitors [SGLT-2is]) can delay chronic kidney disease (CKD) progression, cardiovascular events, and death. METHODS: This observational cohort study used electronic health record and claims data from Japan, Sweden, and the United States to assess 1-year mortality/hospitalization event rates per 100 patient-years (PYs), cumulative hospital healthcare costs per patient, and kidney-protective treatment use before/after SGLT-2i (dapagliflozin) approval for CKD (2021) for patients with CKD stage 3-4 with/without type 2 diabetes (T2D)...
February 1, 2024: Kidney360
#10
JOURNAL ARTICLE
Qian Li, Ke Yin, Hai-Ping Ma, Hui-Hui Liu, Sha Li, Xiao Luo, Rong Hu, Wei-Wei Zhang, Zheng-Sheng Lv, Xiao-Lei Niu, Mei-Hua Gu, Cheng-Lu Li, Yong-Shuang Liu, Yi-Jiang Liu, Hai-Bo Li, Nancy Li, Chong Li, Wendy Wei Gu, Jian-Jun Li
N-acetylgalactosamine (GalNAc)-conjugated small interfering RNA (siRNA) therapies have received approval for treating both orphan and prevalent diseases. To improve in vivo efficacy and streamline the chemical synthesis process for efficient and cost-effective manufacturing, we conducted this study to identify better designs of GalNAc-siRNA conjugates for therapeutic development. Here, we present data on redesigned GalNAc-based ligands conjugated with siRNAs against angiopoietin-like 3 (ANGPTL3) and lipoprotein (a) [Lp(a)] two target molecules with potential to address large unmet medical needs in atherosclerotic cardiovascular diseases (ASCVD)...
January 9, 2024: Molecular Therapy
#11
REVIEW
Abdullah Al-Ashwal, Afaf Alsagheir, Mohammed Al Dubayee, Mutaz Al-Khnifsawi, Ahmed Al-Sarraf, Zuhier Awan, Tawfeg Ben-Omran, Saif Al-Yaarubi, Angham Almutair, Abdelhadi Habeb, Faouzi Maatouk, Manal Alshareef, Naji Kholaif, Dirk Blom
Homozygous familial hypercholesterolaemia (HoFH) is a severe form of FH in which inheritance of two defective or null mutations in genes associated with metabolism of low-density lipoprotein cholesterol (LDL-C) results in extremely high LDL-C, premature atherosclerotic cardiovascular disease (ASCVD) and mortality. Treatment of HoFH comprises a multi-modal approach of statins, ezetimibe, lipoprotein apheresis; and inhibitors of proprotein convertase subtilisin/kexin type, angiopoietin-like protein 3 (ANGPTL3) and microsomal triglyceride transfer protein...
December 15, 2023: Journal of Clinical Lipidology
#12
JOURNAL ARTICLE
Yuri Barbosa Araújo, Ana Beatriz Rocha Almeida, Márcio Fellipe Menezes Viana, Rafael Alexandre Meneguz-Moreno
BACKGROUND: Central illustration : Use of Atherogenic Indices as Assessment Methods of Clinical Atherosclerotic Diseases. BACKGROUND: The search for clinically useful methods to assess atherosclerotic diseases (ASCVD) with good accuracy, low cost, non-invasiveness, and easy handling has been stimulated for years. Thus, the atherogenic indices evaluated in this study may fit this growing demand. OBJECTIVES: To assess the potential of atherogenic indices to evaluate patients with clinical atherosclerosis...
December 2023: Arquivos Brasileiros de Cardiologia
#13
JOURNAL ARTICLE
Noppanat Tiansuwan, Thinnakrit Sasiprapha, Sutipong Jongjirasiri, Nattawut Unwanatham, Ammarin Thakkinstian, Jiraporn Laothamatas, Thosaphol Limpijankit
BACKGROUND: Coronary artery calcium (CAC) scanning is a valuable additional tool for calculating the risk of cardiovascular (CV) events. We aimed to determine if a CAC score could improve performance of a Thai CV risk score in prediction of 10-year atherosclerotic cardiovascular disease (ASCVD) risk for asymptomatic patients with CV risk factors. METHODS: This was a retrospective cohort study that enrolled asymptomatic patients with CV risk factors who underwent CAC scans between 2005 and 2013...
2023: Frontiers in Cardiovascular Medicine
#14
REVIEW
Federica Agnello, Maria Sara Mauro, Carla Rochira, Davide Landolina, Simone Finocchiaro, Antonio Greco, Nicola Ammirabile, Carmelo Raffo, Placido Maria Mazzone, Marco Spagnolo, Giovanni Occhipinti, Antonino Imbesi, Daniele Giacoppo, Davide Capodanno
INTRODUCTION: Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of global mortality, imposing substantial healthcare economic burdens. Among the modifiable risk factors, hypercholesterolemia, especially elevated low-density lipoprotein cholesterol (LDL-C), plays a pivotal role in ASCVD development. Novel therapies such as PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9) inhibitors are emerging to address this concern. These inhibitors offer the potential to reduce cardiovascular risk by directly targeting LDL-C levels...
November 23, 2023: Expert Review of Cardiovascular Therapy
#15
JOURNAL ARTICLE
Xi Tan, Yuanjie Liang, Jigar R Rajpura, Larisa Yedigarova, Josh Noone, Lin Xie, Silvio Inzucchi, Adam de Havenon
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which have proven cardiovascular benefits, are recommended in people with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD). However, there is limited real-world evidence comparing the effects of once-weekly (OW) GLP-1 RAs and dipeptidyl peptidase-4 inhibitors (DPP-4is). This observational cohort study (1/1/2017-9/30/2021) used data from the Optum Clinformatics® Data Mart to compare time to incident clinical cardiovascular outcomes, health care resource utilization (HCRU), and medical costs in new adult users of OW GLP-1 RAs and DPP-4is with T2D and ASCVD...
November 20, 2023: Cardiovascular Diabetology
#16
JOURNAL ARTICLE
Kershaw V Patel, Matthew W Segar, David C Klonoff, Muhammad Shahzeb Khan, Muhammad Shariq Usman, Carolyn S P Lam, Subodh Verma, Andrew P DeFilippis, Khurram Nasir, Stephan J L Bakker, B Daan Westenbrink, Robin P F Dullaart, Javed Butler, Muthiah Vaduganathan, Ambarish Pandey
Background: The optimal approach to identify individuals with diabetes who are at high-risk for developing heart failure (HF) to inform implementation of preventive therapies is unknown, especially in those without atherosclerotic cardiovascular disease (ASCVD). Methods: Adults with diabetes and no HF at baseline from 7 community-based cohorts were included. Participants without ASCVD who were at high-risk for developing HF were identified using 1-step screening strategies: risk score (WATCH-DM≥12); N-terminal pro-B-type natriuretic peptide (NT-proBNP;≥125 pg/mL); high-sensitivity cardiac troponin (hs-cTnT ≥14 ng/L, hs-cTnI≥31 ng/L); echocardiography-based diabetic cardiomyopathy (echo-DbCM; LA enlargement, LV hypertrophy, or diastolic dysfunction)...
November 11, 2023: Circulation
#17
REVIEW
John R Burnett, Amanda J Hooper
INTRODUCTION: Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality worldwide. Lowering LDL-cholesterol, by lifestyle modification or therapeutically, reduces the risk of ASCVD. Proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein which binds to the LDL-receptor and induces degradation, is a clinically validated target to lower LDL-cholesterol. Injectable PCSK9 inhibitor therapies have demonstrated substantial reductions in LDL-cholesterol with associated decreased risk of ASCVD events...
October 10, 2023: Expert Opinion on Investigational Drugs
#18
REVIEW
Miron Sopic, Baiba Vilne, Eva Gerdts, Fábio Trindade, Shizuka Uchida, Soliman Khatib, Stephanie Bezzina Wettinger, Yvan Devaux, Paolo Magni
Multiomics studies offer accurate preventive and therapeutic strategies for atherosclerotic cardiovascular disease (ASCVD) beyond traditional risk factors. By using artificial intelligence (AI) and machine learning (ML) approaches, it is possible to integrate multiple 'omics and clinical data sets into tools that can be utilized for the development of personalized diagnostic and therapeutic approaches. However, currently multiple challenges in data quality, integration, and privacy still need to be addressed...
October 6, 2023: Trends in Molecular Medicine
#19
JOURNAL ARTICLE
Mia E Lussier, Michael R Gionfriddo, Jove H Graham, Eric A Wright
BACKGROUND: Despite type 2 diabetes guidelines recommending against the use of sulfonylureas in older adults and for the use of sodium-glucose cotransporter-2 inhibitors (SGLT2) and glucagon-like peptide-1 agonists (GLP1s) in patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and heart failure (HF), real-world guideline-concordant prescribing remains low. While some factors such as cost have been suggested, an in-depth analysis of the factors associated with guideline-concordant prescribing is warranted...
October 2, 2023: Journal of General Internal Medicine
#20
JOURNAL ARTICLE
Katarina Steen Carlsson, Kristoffer Nilsson, Michael Lyng Wolden, Mads Faurby
AIM: To examine direct and indirect costs, early retirement, cardiovascular events and mortality over 5 years in people with atherosclerotic cardiovascular disease (ASCVD) and matched controls in Sweden. METHODS: Individuals aged ≥ 16 years living in Sweden on 01 January 2012 were identified in an existing database. Individuals with ASCVD were propensity score matched to controls without ASCVD by age, sex and educational status. We compared direct healthcare costs (inpatient, outpatient and drug costs), indirect costs (resulting from work absence) and the risk of stroke, myocardial infarction (MI) and early retirement...
September 29, 2023: BMC Cardiovascular Disorders
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
